This is a pivotal time in the history of the amyloidosis, with a number of new therapies on the horizon. Increasing the level of support is essential for research in these underserved diseases. Researchers, clinicians and partners in the biotech and pharmaceutical industries are working on the development of therapies that are changing the landscape and improving the outlook for patients. Both the Amyloidosis Foundation and the Amyloidosis Research Consortium are committed to serving patient needs by monitoring, supporting and investing in the advancement of scientific and medical progress in the amyloidosis field.
The Amyloidosis Foundation provides annual grants for scientists whose research targets the challenges in the field of amyloidosis.
The Amyloidosis Research Consortium is an innovative model that accelerates key research and actively promotes the collaboration, achievement, and advancement of clinical trials and treatment.
For over a decade, the Amyloidosis Foundation grant program has supported outstanding research in all forms of systemic amyloidosis. Through our research program we encourage, promote and invest in the medical study and exploration of the amyloidosis diseases.
2017 Research Grants
Candidates will have completed their doctoral studies or clinical fellowship within ten years prior to application. Grants are awarded for one year according to the award conditions and reporting guidelines. On request, a second year of funding will be considered, pending review of the research progress and as foundation funding permits. Deadline is now closed.
The foundation is dedicated to encouraging young scientists that show an interest in amyloidosis research, by providing travel grants to physicians and researchers who have completed their medical doctorate or fellowship within the past 10 years. These grants enable participation in the bi-annual International Amyloidosis Symposium.
The Amyloidosis Foundation has a very successful Grand Rounds program, as part of our commitment to raise awareness of the amyloidosis diseases. We will sponsor an expert in amyloidosis to speak to doctors and medical staff regarding the diagnostic tools, clinical protocols and treatment therapies that are currently available.
Our speakers are among the most knowledgeable specialists in the U.S. and are involved in amyloidosis research and patient care. The Amyloidosis Foundation will arrange for the speaker and will cover all travel expenses and honoraria.
Physicians who are available for our Grand Rounds Program include:
Adam Cohen, MD – University of Pennsylvania – Hematology
Raymond Comenzo, MD – Tufts Medical Center – Hematology
Morie Gertz, MD – Mayo Clinic, Rochester – Hematology
Martha Grogan, MD – Mayo Clinic, Rochester – Cardiology
James Hoffman, MD – University of Miami – Hematology
Robert Kyle, MD – Mayo Clinic, Rochester – Hematology
Heather Landau, MD – Memorial Sloan-Kettering – Hematology
Mathew Maurer, MD – Columbia University Medical Ctr. – Cardiology
Raymond Migrino MD – Phoenix Veterans Administration – Cardiology
Vaishali Sanchorawala, MD – Boston University Amyloid Program – Hematology
Adam Segal, MD – Brigham & Women’s Hospital – Nephrology
Marc Semigran, MD – Massachusetts General – Cardiology
Brendan Weiss, MD – University of Pennsylvania – Hematology
Ron Witteles, MD – Stanford University Medical Center – Cardiology
Jeffrey Zonder, MD – Karmanos Cancer Center – Hematology
If you have an interest in having one of our speakers give Grand Rounds on amyloidosis at your medical facility, please email us at email@example.com or call our toll-free number at 1-877-AMYLOID (877-269-5643).
Amyloidosis Research Consortium
The Amyloidosis Research Consortium was formed to help improve the understanding of the systemic amyloid diseases. The consortium brings together experts in the field to work as a team on cutting edge research. The ARC is developing a pipeline of key clinical trials and promising therapies.
This research organization is committed to building relationships among patients, academia, industry, foundations, government, and regulators in order to swiftly deliver new treatments to market. In partnership with the Amyloidosis Foundation, the Amyloidosis Research Consortium is driven by patient needs and dedicated to advocating on their behalf. Amyloidosis Research Consortium
We are proud to feature our annual grant recipients, whose research targets the challenges in the field of amyloidosis.
Heather Landau - MD
Gene Expression Changes in AL amyloidosis
Amyloidosis Foundation - Donald C. Brockman Memorial Research Grant, 2015
Memorial Sloan Kettering Cancer Center, Medicine Division: Hematology
Amyloidosis is caused by the expansion of abnormal plasma cells that produce abnormal proteins that accumulate in tissues to cause end-organ damage. To date, mutations in amyloid-forming plasma cells and their resulting consequences on the genes expressed have been poorly characterized.
This grant from the Amyloidosis Foundation will allow us to perform the first large-scale characterization of the mutations and gene expression changes in AL amyloidosis by evaluating patient’s plasma cells at diagnosis and following treatment. We expect such studies to allow us to identify genes that contribute to the development of disease, predict treatment responses, and identify new therapeutic targets. This study will play an important role in future development of a cure for amyloidosis.
Michael Rosenzweig - MD
Cell Therapy for AL amyloidosis
Amyloidosis Foundation - David Seldin, MD, PhD Memorial Research Grant, 2015
City of Hope, Medicine Division: Hematology & Hematopoietic Cell Transplantation
Amyloid light-chain (AL) amyloidosis is a rare blood disease that is treatable but often fatal. With the help of the Amyloidosis Foundation, we plan to develop a new treatment for AL amyloidosis by genetically engineering a patient's own immune system to recognize and kill the abnormal blood cells when reintroduced into the body.
We will evaluate blood cells in patients with AL for expression of a specific protein that could be targeted by this approach. Once the target is identified, genetically engineered cells will be generated and tested in the laboratory. The ultimate goal is developing this therapy for clinical trials in patients with AL amyloidosis.
Lorena Saelices - PhD
New Strategy for TTR amyloidosis
Amyloidosis Foundation - Research Grant, 2015
Regents of the University of California
Treatments for systemic transthyretin amyloidosis have been held back by lack of information on the structures and causes of aggregation of the amyloid fibers formed by transthyretin (TTR). In previous work, we identified two protein segments involved in TTR aggregation, and developed a novel strategy to inhibit the process by small non-natural peptides.
Based on the amyloid structure of the aggregation-driving segments, we designed two peptide inhibitors that hindered TTR aggregation. With the support of the Amyloidosis Foundation in our research, these peptide inhibitors will be tested for their ability to halt fibril formation in the disease model of fruit flies. This new strategy will assist in providing successful therapies for TTR patients.
Clare-Louise Towse - MChem, MPhil, PhD
Trying to Inhibit Amyloid Formation
Amyloidosis Foundation - Research Grant, 2015
University of Washington, Medicine Division: Office of Research
The proteins involved in amyloid diseases share an intermediate state that forms before the insoluble fibril form found in diseased tissue. This intermediate can be prevented from forming the fibrils by adding peptides, designed by the Daggett lab, in vitro. Our grant from the Amyloidosis Foundation will help us build on these designs by placing them inside a larger protein to increase their structural stability, which in turn is linked to their ability to prevent fibril formation.
We will be optimizing the designed peptides within the protein using computational methods and, once optimized, these molecules will be chemically synthesized and tested for the potential to inhibit amyloid formation. Results from this study will hopefully prevent amyloid formation in the future and give hope to amyloidosis patients.
Guillermo A. Herrera - MD
Stem Cell Research
Amyloidosis Foundation - Research Grant, 2014
Louisiana State University, Medicine Division: Pathology
Kidney involvement and eventual kidney failure are common in amyloidosis. If the kidneys fail, the only options are dialysis and transplantation, both of which can cause significant complications. Today, amyloidosis is diagnosed earlier resulting in prolonged survival. The need for repairing damaged organs is obvious.
This grant from the Amyloidosis Foundation supports our research that investigates the use of stem cells administered intravenously to repair and heal damaged kidneys in an animal model. Stem cells are undifferentiated and can transform into specialized cell types. Results from this study will pave the way to use stem cells in human patients with amyloidosis to improve survival and quality of life.
Jennifer Kollmer - MD
Focusing on ATTR Polyneuropathy
Amyloidosis Foundation - Research Grant, 2014
University of Heidelberg, Medicine Division: Neuroradiology
A severe impairment of the peripheral nerves is one of the main manifestations in hereditary amyloidosis (ATTR). Our grant from the Amyloidosis Foundation aids our research in developing a new and highly sensitive diagnostic tool. The focus of this tool will be to:
1) Detect very early nerve damage in gene-carriers without symptoms (family members of patients who already present with symptomatic disease).
2) Monitor nerve lesions in patients with symptomatic amyloid polyneuropathy under treatment. Our study of participants will be done in different groups of disease severity. We will then perform a MRI of the lower limb peripheral nerves. This will help us find which patient has the highest sensitivity while we detect and define the peripheral nerve damage. We can then determine the stage of polyneuropathy for that patient.
This research will aid in providing earlier treatment for patients after initial diagnosis and in delivering successful therapies for patients with advanced disease.
Rockland L. Wiseman - PhD
New Strategies for Systemic Amyloid Diseases
Amyloidosis Foundation - Research Grant, 2014
The Scripps Research Institute – Department of Molecular & Experimental Medicine
The systemic amyloid diseases are a group of diseases caused by the build-up of unstable proteins that form toxic tangles in the blood. These tangles accumulate on organs such as the heart, gut, and kidney, leading to organ failure and ultimately to death. Currently, no treatment other than invasive surgery exists to treat the majority of these diseases, making systemic amyloid diseases a large, unmet medical need. We are developing new strategies to reduce the lethal accumulation of unstable proteins associated with systemic amyloid diseases by enhancing the natural, protective pathways that regulate the levels of unstable proteins in the blood.
With the help from the Amyloidosis Foundation grant, our research will aid in the establishment of this new strategy. We hope to demonstrate that a single therapeutic approach can be used to treat many different systemic amyloid diseases. Therefore, it may be possible in the future to use a single drug to broadly treat these devastating disorders.
Amyloidosis Foundation - Research Grant, 2013
Tufts Medical Center, Medicine Division: Hematology-Oncology
The support of the Amyloidosis Foundation for our development and testing of a new type of treatment to suppress light chain production by plasma cells has been critical. With this support we have been able to establish that a single type of interfering RNA can be delivered into plasma cells with a profound and rapid effect on the production of light chains that form amyloid.
With the support of this grant we completed lambda light chain gene knockdown on human myeloma cell lines, patient plasma cells and xenograft animal model. The study in human multiple myeloma cell lines (ALMC-1 and ALMC-2) showed that knockdown of the λ light chain constant region IGLCCR causes rapid decrease of IGLC mRNA and λ light chain production in vitro, and activates the unfolded protein response (UPR) in plasma cells producing intact immunoglobulin with a significant up-regulation of terminal UPR and endoplasmic reticulum associated degradation (ERAD) genes (Blood 2014; 3(22):3440-51). The study in plasma cells from 19 AL patient marrow specimens showed that knockdown of IGLC led to a reduction of λ light chain mRNA that strongly correlated with decrease of intracellular LC protein and was also associated with increased caspase 3/7 activity in patient plasma cells producing intact Ig (e.g., IgG λ or IgA λ) ( Blood 2014 ,123(22):3440-51, Proceedings of XIVth ISA 2014). The secreted λ light chain in supernatants of si[IGLCCR] treated plasma cell cultures from bone marrow of AL patients was decreased by 48% to 75% in 3 representative specimens. We applied the one pool of si[IGLCCR] by means of electroporation delivery in vivo into subcutaneous ALMC-1 or ALMC-2 xenograft plasmacytomas in NOD/SCID mice. The median relative expression ratios (si[IGLCCR]/si[-]) of IGLC mRNA were 0.73 (range 0.17-0.97) in ALMC-1 xenograft plasmacytomas (9/12) and 0.37 in ALMC-2 xenograft plasmacytomas (2/2); the secretion of human λ light chain protein in the mice sera was decreased by 4% to 56% two days after IGLC knockdown in 6 mice.
As a result of the success of the work the Amyloidosis Foundation supported, we have initiated collaboration with a bioengineering laboratory that can produce nanoparticles for the delivery of interfering RNA into plasma cells. This collaboration would not have been possible without the instrumental effort of the foundation in supporting research into new therapies for amyloidosis. I, and my lab colleagues, are grateful for the start the Amyloidosis Foundation has given us.
Matt Wolfe - MD, PhD
Researching Cardiac Amyloidosis
Amyloidosis Foundation - Research Grant, 2013
University of Virginia, Medicine Division: Cardiology
My laboratory uses the fruit fly, Drosophila melanogaster, to model human cardiomyopathies and we are using this approach to develop new insights into cardiac amyloidosis. To accomplish this goal, we made transgenic flies that express either normal human transthyretin or a variant of transthyretin that occurs commonly in individuals who have cardiac amyloidosis. The transgenic flies that have a variant of transthyretin develop changes in muscle consistent with changes observed in human amyloidosis and have problems with the way it functions. We also measured cardiac function in the transgenic flies using a method that is similar to echocardiography in humans and found abnormalities. These exciting results suggest that we can use fly genetics to identify new molecules that may prevent or slow the progression of cardiac amyloidosis.
The Amyloidosis Foundation grant has been instrumental in supporting the research in my laboratory. Importantly, we have been able to conduct new studies and advance our understanding of cardiac amyloidosis. Moreover, the Amyloidosis Foundation award has provided resources that allowed us to develop new transgenic mice to complement our studies in flies. We have presented our scientific retreats at Duke University and look forward to future publications. On a personal note, I have a greater appreciation of the complexities of cardiac amyloidosis and the care required for individuals who have this disease.
Jennifer Ellis Ward - PhD
Exploring Ways to Treat Systemic Amyloidosis
Amyloidosis Foundation - Research Grant, 2012
Boston Medical Center, Medicine Division: Hematology-Oncology
My work, which began as a graduate student in Dr. David Seldin’s laboratory at Boston University School of Medicine, has been focused on developing models of AL (light chain) amyloidosis and using these models to test potential therapies. Now that there are effective treatments to stop or stabilize the production of the amyloidogenic protein, such as preventing the production of light chains by targeting the plasma cells, there still remains a burden of amyloid fibrils already deposited in the body. I developed a transgenic mouse that has an amyloidogenic human Lambda 6 Light Chain in its blood and deposits amyloid fibrils in the stomach with age. Tetracycline antibiotics (like doxycycline) have been shown to disrupt amyloid fibrils and prevent fibril formation in mice for transgenic for transthyretin (TTR) in Dr. Saraiva’s laboratory and in models of Alzheimer’s disease. I treated the young AL transgenic mice with doxycycline in their drinking water and observed that amyloid formation was prevented as they aged, dramatically so with the majority of the mice having no detectable amyloid deposits.
With the research grant from the Amyloidosis Foundation, we took the next step to see if doxycycline could disrupt existing amyloid deposits in aged transgenic mice. We did not observe the dramatic total reduction observed with the prevention studies in the young mice. This presented a new challenge to develop a method to quantitate the amount of amyloid in tissue to determine how much, if any, partial response was achieved and to expand that method to be higher throughput. The Congo-red based fluorescence assay developed is being validated with ex vivo tissue fibrils and being used to study the aggregation of different light chains, including Kappa and Lambda. This method was described in a poster at the XIV International Symposium on Amyloidosis in Indianapolis in 2014 and will be submitted as a manuscript for publication. This aspect of the project has been developed by a talented technician in the laboratory, Varuna Shibad, who will be pursuing a PhD to begin her research career.
Another question that I addressed with the support of this research grant was whether any of the other tetracycline derivative drugs were more effective than doxycycline at disrupting amyloid fibrils. Other antibiotics in the tetracycline family (such as minocycline) have different characteristics that affect their half-life in the blood or ability to get into tissues where amyloid deposits form. We are also interested in compounds derived from tetracyclines that do not have antibiotic activity, but may still disrupt amyloid fibrils, as these may have lesser side effects. We have tested one novel compound so far. Again, the challenge arose that we needed to develop better methods to quantitatively measure amyloid fibrils, especially in the presence of tetracycline drugs, which are fluorescent yellow. The data were also presented in a poster at the XIV International Symposium on Amyloidosis in Indianapolis. We are working to further understand the mechanism of fibril disruption with tetracyclines and are preparing this data for publication.
The grant from the Amyloidosis Foundation is very important as it is extremely difficult to get funding to study rare diseases, especially for scientists who are in the early stages of their career. Many of the traditional funding mechanisms to explore new, pilot projects have been eliminated. I am extremely grateful for the Amyloidosis Foundation’s support of junior researchers which has allowed me, as a basic scientist, to generate data for publication and future grant applications and continue exploring ways to treat systemic amyloidosis.